
Advanced Enzyme Technologies Gears Up for Q3 Reveal on 31st January; Check Key Expectations Here
Click and Sign Up to Get Live Updates on Q3 Results
Updated: 30 Jan 2026 • 5:10 pm
Posted by:

Advanced Enzyme Technologies's Q3 results FY26 are scheduled to be announced on 31st January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.
Advanced Enzyme Technologies Q3 Results 2026 Preview
- Advanced Enzyme Technologies' revenue is expected to be in the range of ₹169.11 crore, a 15.75% YoY increase.
- Profit After Tax, or PAT, is projected to rise by 14.66% YoY.
- Net profit is ₹37.65 crore, a rise of 14.66% YoY
- EBITDA to rise 38.06%
Advanced Enzyme Technologies Share Performance
- Over the past six months, Advanced Enzyme Technologies' share price has fallen by 8.95% to ₹28.00.
- Moreover, over the past year, the stock has increased by 12.87%.
- Despite this weak short-term performance, Advanced Enzyme Technologies' stock has delivered a financially sound 239.85% return over the past 5 years.
- As of 29th January 2026, the stock traded at ₹28.00 per share.
Key Factors to Watch for Advanced Enzyme Technologies Q3 Results FY26
- Revenue & Segment Growth: Check overall sales performance and how key verticals like Human Nutrition, Animal Nutrition, Bio‑Processing and Specialized Manufacturing are trending, as these diversifications drive topline strength.
- Profitability & Margins: Watch EBITDA and net profit margins, especially given recent cost pressures from raw materials and logistics that have affected margins in prior quarters.
- Order & Geographic Mix: Contribution from international markets vs domestic sales, including exports and region‑wise demand shifts, which can influence growth visibility.
- R&D & New Product Pipeline: Progress on R&D initiatives and new enzyme/probiotic solutions, including any new product launches or approvals that could catalyse future growth.
- Raw Material & Input Costs: Impact of raw material price volatility and supply‑chain issues on costs and margins — an important driver of operating performance.
Final Thoughts
Advanced Enzyme Technologies will announce its Q3 FY26 results on 30th January 2026. Analysts expect 4.30% YoY revenue growth, a 1.67% rise in PAT, and a 4.33% fall in EBITDA. Advanced Enzyme Technologies focuses on developing and supplying eco-friendly enzyme and probiotic solutions for healthcare, nutrition, and industrial applications globally.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Recent Articles
Capital Small Finance Bank Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Carborundum Universal Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Capri Global Capital Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Digitide Solutions Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Flair Writing Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
GHCL Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Apar Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Apollo Pipes Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Recent Articles

Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
30 October 2026

Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
30 October 2026

Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
30 October 2026

Greaves Cotton Share Price Jumps 10% Despite 81% Fall in Q2 Profit: What Is Driving the Rally?
30 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
Greaves Cotton Share Price Jumps 10% Despite 81% Fall in Q2 Profit: What Is Driving the Rally?
Asian Paints Share Price After Q2 Results: Profit Up 7%, but Price Hikes Are Yet to Brighten Margins

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





